• The 12-month cumulative incidence of VTE is currently 3% after cancer diagnosis, which is ninefold higher than in the general population.

  • For the past 2 decades, cancer patients’ VTE risk increased threefold overall and sixfold in those using chemotherapy or targeted therapy.

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved survival, and high-resolution imaging. Danish medical registries were used to identify 499 092 patients with a first-time cancer diagnosis between 1997 and 2017, who were matched to 1 497 276 comparison individuals without cancer from the general population. We computed cumulative incidences of VTE 6 and 12 months after the diagnosis/index date. Hazard ratios (HRs) were calculated using Cox regression. Risk factors were examined by computing subdistribution hazard ratios (SHRs) in a competing-risk analysis. Cumulative incidence of VTE 12 months after the cancer diagnosis/index date was 2.3% (95% confidence interval [CI], 2.2% to 2.3%) in the cancer cohort and 0.35% (95% CI, 0.34% to 0.36%) in the comparison cohort (HR, 8.5; 95% CI, 8.2-8.8). Important risk factors for cancer patients were prior VTE (SHR, 7.6; 95% CI, 7.2-8.0), distant metastasis (SHR, 3.2; 95% CI, 2.9-3.4), and use of chemotherapy (SHR, 3.4; 95% CI, 3.1-3.7), protein kinase inhibitors (SHR, 4.1; 95% CI, 3.4-4.9), antiangiogenic therapy (SHR, 4.4; 95% CI, 3.8-5.2), and immunotherapy (SHR, 3.6; 2.8-4.6). Twelve-month incidence in the cancer cohort increased from 1.0% (95% CI, 0.9% to 1.2%) in 1997 to 3.4% (95% CI, 2.9% to 4.0%) in 2017, which was paralleled by improved 12-month survival and increased use of computed tomography scans, chemotherapy, and targeted therapies. In conclusion, the risk of VTE in cancer patients is increasing steadily and is ninefold higher than in the general population.

1.
Bouillard
J
,
Bouillaud
S
.
De l’Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general
.
Arch Gen Med
.
1823
;
1
:
188
-
204
.
2.
Lloyd
AJ
,
Dewilde
S
,
Noble
S
,
Reimer
E
,
Lee
AYY
.
What impact does venous thromboembolism and bleeding have on cancer patients’ quality of life?
Value Health
.
2018
;
21
(
4
):
449
-
455
.
3.
Khorana
AA
,
Francis
CW
,
Culakova
E
,
Kuderer
NM
,
Lyman
GH
.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
.
J Thromb Haemost
.
2007
;
5
(
3
):
632
-
634
.
4.
Khorana
AA
,
Dalal
MR
,
Lin
J
,
Connolly
GC
.
Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
.
Clinicoecon Outcomes Res
.
2013
;
5
:
101
-
108
.
5.
Sørensen
HT
,
Mellemkjaer
L
,
Olsen
JH
,
Baron
JA
.
Prognosis of cancers associated with venous thromboembolism
.
N Engl J Med
.
2000
;
343
(
25
):
1846
-
1850
.
6.
Claus
EB
.
Risk models in genetic epidemiology
.
Stat Methods Med Res
.
2000
;
9
(
6
):
589
-
601
.
7.
Shapiro
CL
.
Cancer survivorship
.
N Engl J Med
.
2018
;
379
(
25
):
2438
-
2450
.
8.
Quaresma
M
,
Coleman
MP
,
Rachet
B
.
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study
.
Lancet
.
2015
;
385
(
9974
):
1206
-
1218
.
9.
Trotter
JP
.
Patient registries: a new gold standard for “real world” research
.
Ochsner J
.
2002
;
4
(
4
):
211
-
214
.
10.
Khorana
AA
,
Francis
CW
,
Culakova
E
,
Kuderer
NM
,
Lyman
GH
.
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
.
Cancer
.
2007
;
110
(
10
):
2339
-
2346
.
11.
White
RH
,
Chew
HK
,
Zhou
H
, et al
.
Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults
.
Arch Intern Med
.
2005
;
165
(
15
):
1782
-
1787
.
12.
Blix
K
,
Brækkan
SK
,
le Cessie
S
,
Skjeldestad
FE
,
Cannegieter
SC
,
Hansen
JB
.
The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study
.
Eur J Epidemiol
.
2014
;
29
(
4
):
277
-
284
.
13.
Cronin-Fenton
DP
,
Søndergaard
F
,
Pedersen
LA
, et al
.
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006
.
Br J Cancer
.
2010
;
103
(
7
):
947
-
953
.
14.
Jensvoll
H
,
Severinsen
MT
,
Hammerstrøm
J
, et al
.
Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort
.
Clin Epidemiol
.
2015
;
7
:
401
-
410
.
15.
Cohen
AT
,
Katholing
A
,
Rietbrock
S
,
Bamber
L
,
Martinez
C
.
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study
.
Thromb Haemost
.
2017
;
117
(
1
):
57
-
65
.
16.
Blix
K
,
Gran
OV
,
Severinsen
MT
, et al
.
Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort
.
J Thromb Haemost
.
2018
;
16
(
7
):
1327
-
1335
.
17.
Schmidt
M
,
Schmidt
SAJ
,
Adelborg
K
, et al
.
The Danish health care system and epidemiological research: from health care contacts to database records
.
Clin Epidemiol
.
2019
;
11
:
563
-
591
.
18.
Sundbøll
J
,
Adelborg
K
,
Munch
T
, et al
.
Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study
.
BMJ Open
.
2016
;
6
(
11
):
e012832
.
19.
Schmidt
M
,
Pedersen
L
,
Sørensen
HT
.
The Danish Civil Registration System as a tool in epidemiology
.
Eur J Epidemiol
.
2014
;
29
(
8
):
541
-
549
.
20.
Gjerstorff
ML
.
The Danish Cancer Registry
.
Scand J Public Health
.
2011
;
39
(
suppl 7
):
42
-
45
.
21.
Schmidt
M
,
Schmidt
SA
,
Sandegaard
JL
,
Ehrenstein
V
,
Pedersen
L
,
Sørensen
HT
.
The Danish National Patient Registry: a review of content, data quality, and research potential
.
Clin Epidemiol
.
2015
;
7
:
449
-
490
.
22.
Adelborg
K
,
Corraini
P
,
Darvalics
B
, et al
.
Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study
.
J Thromb Haemost
.
2019
;
17
(
8
):
1305
-
1318
.
23.
Charlson
ME
,
Pompei
P
,
Ales
KL
,
MacKenzie
CR
.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
.
J Chronic Dis
.
1987
;
40
(
5
):
373
-
383
.
24.
Pottegård
A
,
Schmidt
SAJ
,
Wallach-Kildemoes
H
,
Sørensen
HT
,
Hallas
J
,
Schmidt
M
.
Data Resource Profile: The Danish National Prescription Registry
.
Int J Epidemiol
.
2017
;
46
(
3
):
798
-
798f
.
25.
Fine
JP
,
Gray
RJ
.
A Proportional Hazards Model for the Subdistribution of a Competing Risk
.
J Am Stat Assoc
.
1999
;
94
(
446
):
496
-
509
.
26.
Jonckheere
AR
.
A distribution-free k-sample test against ordered alternatives
.
Biometrika
.
1954
;
41
(
1-2
):
133
-
145
.
27.
Mulder
FI
,
Di Nisio
M
,
Ay
C
, et al
.
Clinical implications of incidental venous thromboembolism in cancer patients
.
Eur Respir J
.
2020
;
55
(
2
):
1901697
.
28.
Kraaijpoel
N
,
Bleker
SM
,
Meyer
G
, et al;
UPE investigators
.
Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study
.
J Clin Oncol
.
2019
;
37
(
20
):
1713
-
1720
.
29.
Streiff
MB
,
Holmstrom
B
,
Ashrani
A
, et al
.
Cancer-associated venous thromboembolic disease, version 1.2015: featured updates to the NCCN Guidelines
.
J Natl Compr Cancer Netw
.
2015
;
13
(
9
):
1079
-
1095
.
30.
Key
NS
,
Khorana
AA
,
Kuderer
NM
, et al
.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update
.
J Clin Oncol
.
2020
;
38
(
5
):
496
-
520
.
31.
Farge
D
,
Frere
C
,
Connors
JM
, et al;
International Initiative on Thrombosis and Cancer (ITAC) advisory panel
.
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
.
Lancet Oncol
.
2019
;
20
(
10
):
e566
-
e581
.
32.
Baron
JA
,
Gridley
G
,
Weiderpass
E
,
Nyrén
O
,
Linet
M
.
Venous thromboembolism and cancer
.
Lancet
.
1998
;
351
(
9109
):
1077
-
1080
.
33.
Sørensen
HT
,
Mellemkjaer
L
,
Steffensen
FH
,
Olsen
JH
,
Nielsen
GL
.
The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
.
N Engl J Med
.
1998
;
338
(
17
):
1169
-
1173
.
34.
Sørensen
HT
,
Sværke
C
,
Farkas
DK
, et al
.
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer
.
Eur J Cancer
.
2012
;
48
(
4
):
586
-
593
.
35.
Carrier
M
,
Lazo-Langner
A
,
Shivakumar
S
, et al;
SOME Investigators
.
Screening for occult cancer in unprovoked venous thromboembolism
.
N Engl J Med
.
2015
;
373
(
8
):
697
-
704
.
36.
van Es
N
,
Di Nisio
M
,
Cesarman
G
, et al
.
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study
.
Haematologica
.
2017
;
102
(
9
):
1494
-
1501
.
37.
Walker
AJ
,
Card
TR
,
West
J
,
Crooks
C
,
Grainge
MJ
.
Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases
.
Eur J Cancer
.
2013
;
49
(
6
):
1404
-
1413
.
38.
Timp
JF
,
Braekkan
SK
,
Versteeg
HH
,
Cannegieter
SC
.
Epidemiology of cancer-associated venous thrombosis
.
Blood
.
2013
;
122
(
10
):
1712
-
1723
.
39.
Yu
Y-B
,
Gau
J-P
,
Liu
C-Y
, et al
.
A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system
.
Thromb Haemost
.
2012
;
108
(
2
):
225
-
235
.
40.
Khorana
AA
,
Soff
GA
,
Kakkar
AK
, et al;
CASSINI Investigators
.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
720
-
728
.
41.
Carrier
M
,
Abou-Nassar
K
,
Mallick
R
, et al
.
Apixaban to prevent venous thromboembolism in patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
711
-
719
.
You do not currently have access to this content.

Sign in via your Institution

Sign In